Amgen and AbbVie have joined existing backers including Merck and Alphabet for a round led by the corporate and UK government-backed Dementia Discovery Fund.
US-biotechnology company Alector has obtained $29.5m in series D funding in a round led by the multi-corporate and UK government-backed Dementia Discovery Fund.
The round was supported by Amgen Ventures, a subsidiary of biopharmaceutical company Amgen; GV, the corporate venturing unit formerly known as Google Ventures; Merck Research Lab (MRL) Ventures, a seed-stage fund of pharmaceutical firm Merck; and pharmaceutical firm AbbVie.
The corporates were joined by OrbiMed, Polaris Partners, Topspin Partners and Mission Bay Capital.
Founded in 2013, Alector…
